GlassScriptPhysician profile
Amy L Quinn
NPI 1598221335
$8,424.10
in general payments reported to CMS, 2019-2025
31 companies · $3,047 in 2025
The $3,047 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,120 · 2022: $1,388 · 2023: $1,040 · 2024: $1,829 · 2025: $3,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,063.19 | 2021-2025 | Rexulti |
| Abbvie INC. | $1,289.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $638.09 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $635.62 | 2021-2025 | Caplyta |
| Corium, LLC | $608.29 | 2022-2025 | Azstarys |
| Alkermes, INC. | $410.41 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $394.82 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $366.76 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $337.40 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $202.50 | 2022-2024 | Jornay Pm |
| Lilly USA, LLC | $187.15 | 2021-2022 | |
| Neos Therapeutics, LP | $187.11 | 2023-2025 | Adzenys Xr-Odt |
| Biogen, INC. | $155.59 | 2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $145.51 | 2025 | Auvelity |
| Amgen INC. | $141.58 | 2021-2023 | Repatha, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.12 | 2022-2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $104.63 | 2021 | |
| Tris Pharma INC | $85.68 | 2024-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $56.10 | 2022 | |
| Noven Therapeutics, LLC | $38.26 | 2025 | Xelstrym |
| Astellas Pharma US INC | $36.06 | 2023-2024 | Myrbetriq, Veozah |
| Neurocrine Biosciences, INC. | $32.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.59 | 2023-2024 | Breztri |
| Vertical Pharmaceuticals, LLC | $20.44 | 2025 | Relexxii |
| Exact Sciences Corporation | $19.83 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $19.79 | 2024 | Keveyis |
| Collegium Pharmaceutical, INC. | $19.36 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $17.89 | 2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $15.35 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.